Relationship between cataract extraction and IOP

Article

Cataract extraction could reduce complications in XFS

"We believe that timely cataract extraction could prevent complications of expected exfoliation syndrome (XFS)," asserted Professor Petja Vassileva when discussing the work she and her colleague, Dr M. Sredkova, performed on the influence of cataract extraction on intraocular pressure (IOP) in patients with XFS and exfoliation glaucoma (XFG), recently presented at the 2011 ESCRS Congress.

Debated topic

There has been much debate on the issue of management of coexisting glaucoma and cataract over the years with an emphasis on primary angle-closure and primary open-angle glaucoma (POAG). "There is a lot of data in the literature, starting in the middle of the 90s with the influence of cataract extraction, especially phaco, on the intraocular pressure (IOP)," Prof. Vassileva added.1

Important clinical implications

"XFS is an age-related systemic disorder and all of the manifestations are severe and have important clinical implications," she said. This cause of glaucoma is common and easily identifiable. "We all know that XFS is typical above the age of 50 and its prevalence increases with age. It's usually associated with a combination of glaucoma with increased pressure and an increased prevalence of cataract," she said. "Many patients with XFS have elevated IOP leading to a development of glaucoma and 50% of eyes undergo cataract surgery after trabeculectomy."

Prof. Vassileva explained that several important but simple questions should be posed in relation to the management of coexisting glaucoma and cataract, for example, should cataract surgery alone be performed? Should cataract surgery be performed first followed by glaucoma surgery, if required? Or, glaucoma surgery first and then definitely follow with cataract surgery?

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.